Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosisStephen G. Smoots, Todd M. Pitts|Breast Cancer Research|2024Cited by 26